Biogen Inc
European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The European Commission, the EU’s executive body, has a final say in Leqembi’s approval. But it almost always follows the drug regulator’s recommendations. […]
Read More
Investors want proof AI will aid drug discovery. Evidence may come in the second half
As investors peer into the future to envision which industries are ripe to be reshaped and energized by artificial intelligence, drug discovery is fast emerging as an obvious choice. Each new drug that hits the market is the product of billions of dollars in investment, often taking at least a decade to get there. The […]
Read More
FDA approval of Eli Lilly’s Alzheimer’s drug cements our decision not to take profits
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Rally in markets: Stocks were higher across the board Tuesday afternoon, led by the Nasdaq Composite , which added 0.7% and was on pace for back-to-back […]
Read More
Eli Lilly assures investors it can overcome the high-quality problem of too much demand
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in the three months ended March […]
Read More
Stocks making the most important moves midday: Tesla, Hilton, Boeing, Mattel and more
Examine out the companies building headlines in midday buying and selling: Boeing — The aerospace big fell 1.5% even after noting that it burned as a result of $3.9 billion in money in the first quarter. The funds melt away was lessen than what analysts had feared. Boeing also posted an adjusted decline of $1.13 […]
Read More
Shares creating the greatest moves premarket: Boeing, Tesla, Visa, Airbnb and far more
Look at out the companies generating headlines right before the bell. Boeing — Shares jumped 3% soon after Boeing posted a narrower-than-expected loss in its latest results. In its first quarter, the firm reported an altered decline of $1.13 for every share, far better than the modified loss of $1.76 per share estimated by the […]
Read More
Biogen tops profit estimates as cost cuts take hold, Alzheimer’s drug Leqembi launch picks up
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected. Biogen and […]
Read More
Hundreds of analysts slice their cost targets on these 10 stocks ahead of earnings
Analysts have reduced their anticipations on many global stocks this week by slicing their price tag targets. The list of stocks includes automobile stocks Tesla , Rivian and Aptiv , pharmaceutical corporations Biogen and Novartis , energy corporations EQT Corp and TotalEnergies , airline Deutsche Lufthansa and aerospace business Boeing , and quickly meals large […]
Read More
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg | Getty […]
Read More
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
Good afternoon! The launch of the closely watched Alzheimer’s drug Leqembi is off to a slow start. Still, demand for the treatment from Biogen and its Japanese partner Eisai is rising. That’s the update the two drugmakers gave Wall Street during their latest quarterly earnings calls earlier this month. But before we get into the numbers, […]
Read More